From the Research
Platelet Count and Lovenox (Enoxaparin) Contraindication
- The contraindication of Lovenox (enoxaparin) at a specific platelet count is not explicitly stated in the provided studies.
- However, the studies suggest that enoxaparin can be safely administered at a platelet count in the range of 20 and 55 x 10(9)/l in certain patient populations 1.
- A study published in 2017 reported that guidelines for enoxaparin dose modification in patients with cancer and thrombocytopenia suggest holding anticoagulation for a platelet count <25,000/mcL 2.
- Another study published in 2004 reported that enoxaparin treatment was safe and efficacious in patients with acute leukemia and venous thromboembolic disease, even when the platelet count was below 20,000 x 10(9)/L, with a reduced dose of 50% 3.
- It is essential to note that these studies have different patient populations and contexts, and the platelet count at which enoxaparin is contraindicated may vary depending on the specific situation.
- The decision to administer enoxaparin should be made on a case-by-case basis, taking into account the individual patient's risk factors and medical history 1, 2, 3.